Effects of Dietary Nutrients on Liver and Adipose Tissue Metabolism

The Effect of Short-term Overconsumption of Specific Dietary Nutrients on Liver and Adipose Tissue Metabolism

In health,adipose tissue stores fat from the diet. If the fat tissue stops storing dietary fat then this increases the chance of it being stored in the liver, which is related to increased risk of heart disease and type 2 diabetes. It has been suggested that having a diet high in sugars or certain fats, may cause the fat tissue and liver to change how they function; we would like to investigate this in detail.

Study Overview

• Status: Recruiting
• Conditions: NAFLD; Nutrient; Excess
• Intervention / Treatment: Other: Overconsumption of specific dietary nutrient

Detailed Description

This research aims to investigate how the overconsumption of specific macronutrients may effect adipose tissue and liver metabolism and function. Liver and heart fat content and adipose tissue and liver metabolism fasting and postprandial lipid metabolism will be assessed before and after the specific dietary intervention.

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Leanne Hodson, PhD; Phone Number: +441865857224; Email: leanne.hodson@ocdem.ox.ac.uk

Study Locations

• United Kingdom
  • Oxford, United Kingdom, OX3 7LE
    • Recruiting
    • Oxford Centre for Diabetes, Endocrinology and Metabolism
    • Contact: Rachel Craven-Todd; Phone Number: +441865857331; Email: rachel.craven-todd@ocdem.ox.ac.uk
    • Principal Investigator: Leanne Hodson, PhD
    • Contact: Louise Dennis, MSc; Phone Number: +441865 857 203; Email: louise.dennis@ocdem.ox.ac.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participant is willing and able to give informed consent for participation in the study.
• Male or Female, aged ≥18 or ≤65 years.
• Body Mass Index ≥19 ≤35 kg/m2
• No medical condition or relevant drug therapy known to affect liver or adipose tissue metabolism.
• Weight stable for the previous 3 months

Exclusion Criteria:

• Patient is unwilling or unable to give informed consent for participation in the study
• A blood haemoglobin <135mg/dL for men and <120mg/dL for women
• Donated (or lost) ≥250 ml of blood in the previous two months.
• On a weight loss diet or have decreased their body weight by >5% in the previous 3 months.
• Have increased their body weight by >5% in the previous 3 months.
• Any metabolic condition or relevant drug therapy
• Current smoker
• History of alcoholism or a greater than recommended alcohol intake (>30 g of alcohol daily for men and >20 g of alcohol daily for women)
• Haemorrhagic disorders
• Anticoagulant treatment
• History of albumin allergy
• Pregnant or nursing mothers
• Women who are taking any contraceptive agent or device including oral contraceptives, hormone replacement therapy (HRT) or who have used these within the last 12 months
• History of severe claustrophobia
• Presence of metallic implants, pacemaker, or are unwilling to remove any piercings
• History of an eating disorder or any other psychological condition that may affect the participants ability to adhere to study intervention/experimental diets.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High-sugar diet; Participants will be asked to consume a relatively low-fat, high-carbohydrate eucaloric diet enriched in free-sugars (20% total energy).	Other: Overconsumption of specific dietary nutrient; Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Liver de novo lipogenesis	Investigators will utilise stable isotope tracer methodology to measure the change in the contribution of newly synthesised fatty acids to very low density lipoprotein triglyceride	Within 21 days after starting the intervention diet

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adipose tissue metabolism	Investigators will measure the change in the expression of key lipogenic genes in subcutaneous adipose tissue	Within 21 days after starting the intervention diet
Liver fat accumulation	Investigators will measure the change in the amount of fat within the liver using MRI/S	Within 21 days after starting the intervention diet

Collaborators and Investigators

• Sponsor: University of Oxford

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2017
• Primary Completion (Anticipated): March 31, 2023
• Study Completion (Anticipated): March 31, 2023

Study Registration Dates

• First Submitted: March 20, 2017
• First Submitted That Met QC Criteria: March 20, 2017
• First Posted (Actual): March 24, 2017

Study Record Updates

• Last Update Posted (Actual): June 7, 2022
• Last Update Submitted That Met QC Criteria: June 6, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: Oxlip-2017-BBSRC/BHF

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Following completion of the study, all individual data obtained from participants may potentially be shared with other researchers, both here in the United Kingdom and abroad, in appropriate circumstances. If data is to be shared with other researchers, it will be done so under fully anonymised conditions.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No